Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

Rüdiger Hehlmann; Michael Lauseker; Susanne Jung-Munkwitz; Armin Leitner; Martin C Müller; Nadine Pletsch; Ulrike Proetel; Claudia Haferlach; Brigitte Schlegelberger; Leopold Balleisen; Mathias Hänel; Markus Pfirrmann; Stefan W Krause; Christoph Nerl; Hans Pralle; Alois Gratwohl; Dieter Hossfeld; Joerg Hasford; Andreas Hochhaus; Susanne Saussele

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

Standard

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. / Hehlmann, Rüdiger; Lauseker, Michael; Jung-Munkwitz, Susanne; Leitner, Armin; Müller, Martin C; Pletsch, Nadine; Proetel, Ulrike; Haferlach, Claudia; Schlegelberger, Brigitte; Balleisen, Leopold; Hänel, Mathias; Pfirrmann, Markus; Krause, Stefan W; Nerl, Christoph; Pralle, Hans; Gratwohl, Alois; Hossfeld, Dieter; Hasford, Joerg; Hochhaus, Andreas; Saussele, Susanne.

in: J CLIN ONCOL, Jahrgang 29, Nr. 12, 12, 2011, S. 1634-1642.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hehlmann, R, Lauseker, M, Jung-Munkwitz, S, Leitner, A, Müller, MC, Pletsch, N, Proetel, U, Haferlach, C, Schlegelberger, B, Balleisen, L, Hänel, M, Pfirrmann, M, Krause, SW, Nerl, C, Pralle, H, Gratwohl, A, Hossfeld, D, Hasford, J, Hochhaus, A & Saussele, S 2011, 'Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.', J CLIN ONCOL, Jg. 29, Nr. 12, 12, S. 1634-1642. <http://www.ncbi.nlm.nih.gov/pubmed/21422420?dopt=Citation>

APA

Hehlmann, R., Lauseker, M., Jung-Munkwitz, S., Leitner, A., Müller, M. C., Pletsch, N., Proetel, U., Haferlach, C., Schlegelberger, B., Balleisen, L., Hänel, M., Pfirrmann, M., Krause, S. W., Nerl, C., Pralle, H., Gratwohl, A., Hossfeld, D., Hasford, J., Hochhaus, A., & Saussele, S. (2011). Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J CLIN ONCOL, 29(12), 1634-1642. [12]. http://www.ncbi.nlm.nih.gov/pubmed/21422420?dopt=Citation

Vancouver

Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J CLIN ONCOL. 2011;29(12):1634-1642. 12.

Bibtex

@article{9a75a4fbe19747b5844de6113a69a4fa,

title = "Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.",

abstract = "Treatment of chronic-phase (CP) chronic myeloid leukemia (CML) with imatinib 400 mg/d can be unsatisfactory. Optimization of treatment is warranted.",

keywords = "Adult, Germany, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Risk Factors, Adolescent, Young Adult, Treatment Outcome, Risk Assessment, Survival Rate, Time Factors, Disease-Free Survival, Chi-Square Distribution, Remission Induction, Kaplan-Meier Estimate, Dose-Response Relationship, Drug, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Interferon-alpha/administration & dosage, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/*drug therapy/genetics/mortality, Piperazines/administration & dosage, Protein Kinase Inhibitors/administration & dosage, Pyrimidines/administration & dosage, Adult, Germany, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Risk Factors, Adolescent, Young Adult, Treatment Outcome, Risk Assessment, Survival Rate, Time Factors, Disease-Free Survival, Chi-Square Distribution, Remission Induction, Kaplan-Meier Estimate, Dose-Response Relationship, Drug, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Interferon-alpha/administration & dosage, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/*drug therapy/genetics/mortality, Piperazines/administration & dosage, Protein Kinase Inhibitors/administration & dosage, Pyrimidines/administration & dosage",

author = "R{\"u}diger Hehlmann and Michael Lauseker and Susanne Jung-Munkwitz and Armin Leitner and M{\"u}ller, {Martin C} and Nadine Pletsch and Ulrike Proetel and Claudia Haferlach and Brigitte Schlegelberger and Leopold Balleisen and Mathias H{\"a}nel and Markus Pfirrmann and Krause, {Stefan W} and Christoph Nerl and Hans Pralle and Alois Gratwohl and Dieter Hossfeld and Joerg Hasford and Andreas Hochhaus and Susanne Saussele",

year = "2011",

language = "English",

volume = "29",

pages = "1634--1642",

journal = "J CLIN ONCOL",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "12",

}

RIS

TY - JOUR

T1 - Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

AU - Hehlmann, Rüdiger

AU - Lauseker, Michael

AU - Jung-Munkwitz, Susanne

AU - Leitner, Armin

AU - Müller, Martin C

AU - Pletsch, Nadine

AU - Proetel, Ulrike

AU - Haferlach, Claudia

AU - Schlegelberger, Brigitte

AU - Balleisen, Leopold

AU - Hänel, Mathias

AU - Pfirrmann, Markus

AU - Krause, Stefan W

AU - Nerl, Christoph

AU - Pralle, Hans

AU - Gratwohl, Alois

AU - Hossfeld, Dieter

AU - Hasford, Joerg

AU - Hochhaus, Andreas

AU - Saussele, Susanne

PY - 2011

Y1 - 2011

N2 - Treatment of chronic-phase (CP) chronic myeloid leukemia (CML) with imatinib 400 mg/d can be unsatisfactory. Optimization of treatment is warranted.

AB - Treatment of chronic-phase (CP) chronic myeloid leukemia (CML) with imatinib 400 mg/d can be unsatisfactory. Optimization of treatment is warranted.

KW - Adult

KW - Germany

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Risk Factors

KW - Adolescent

KW - Young Adult

KW - Treatment Outcome

KW - Risk Assessment

KW - Survival Rate

KW - Time Factors

KW - Disease-Free Survival

KW - Chi-Square Distribution

KW - Remission Induction

KW - Kaplan-Meier Estimate

KW - Dose-Response Relationship, Drug

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use

KW - Interferon-alpha/administration & dosage

KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/drug therapy/genetics/mortality

KW - Piperazines/administration & dosage

KW - Protein Kinase Inhibitors/administration & dosage

KW - Pyrimidines/administration & dosage